SEC Filing · 424B3
Biodexa Pharmaceuticals Plc
SEC Filing
Company context
We are a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, including gastrointestinal stromal tumors (“GIST”), familial adenomatous polyposis (“FAP”), non-muscle invasive bladder cancer (“NMIBC”), and type 1 diabetes (“T1D”).
Current securities
As-filed source
As filedOpen full document ↗